Background: Extranodal natural killer/T-cell lymphoma (NKTCL) is a clinically heterogeneous disease with a poor prognosis, requiring risk-stratified management in affected patients. Recently, tumor microenvironment including regulatory T cells (Tregs) has been implicated as a prognostic marker in certain types of lymphoma.
introduction
Extranodal natural killer/T-cell lymphoma (NKTCL) usually derived from natural killer (NK) cells or, rarely, from cytotoxic T cells. Characteristically, Epstein-Barr virus (EBV) latently infected tumor cells in nearly all NKTCLs. NKTCL is common in East Asians and Mexicans, but rare in Western populations. NKTCL most frequently presents in the upper aerodigestive tract (UAT); however, it can also involve variable extranodal sites [1] . NKTCL patients are often refractory to radio-or chemotherapy and show aggressive behaviors with poor clinical outcome [2] . Therefore, risk stratification of NKTCL is important for the appropriate management of affected patients.
However, the role of alleged risk factors of non-Hodgkin's lymphoma creates limitations in evaluating the prognosis of NKTCL patients. For instance, results conflict as to the prognostic impact of the International Prognostic Index (IPI) score in NKTCL [2, 3] . The recently proposed natural killer/Tcell lymphoma Prognostic Index (NKPI), based on B symptoms, stage, lactate dehydrogenase (LDH) level, and regional lymph node involvement, has failed to predict the outcome of NKTCL patients in a few subsequent studies, especially in NKTCLs arising in non-UAT area [4, 5] . NKTCL, when presenting at sites other than the UAT, exhibited poor prognosis compared with those presenting at the UAT [1, 5, 6] . Local invasiveness was even more predictive of survival than IPI in early-stage NKTCLs [7] . This clinical heterogeneity and the controversial issues on the prognostic factors impose requirements for a new approach to dealing with NKTCL.
Regulatory T cells (Tregs) play an important role in the suppression of immune response and the maintenance of immune tolerance. Through variable mechanisms, Tregs inhibit many adaptive and innate immune cells, including CD4+ T cells, CD8+ T cells, dendritic cells, macrophages, NKT cells, and B cells [8] . In recent years, it has been shown that Tregs also inhibit NK cells in a transforming growth factor-b (TGFb)-dependent manner [9] [10] [11] . Overall, Tregs contribute to the inhibition of the autoimmune reaction to self-antigen and to the prevention of graft rejection in organ transplantation [8] . However, in terms of tumor immunity, Tregs interfere with the effective antitumor immune responses and thereby contribute to tumor growth and progression [12] . Therefore, in patients afflicted with solid tumors such as stomach, lung, and ovary cancers, increased numbers of tumor-infiltrating Tregs were associated with a poor prognosis [13] [14] [15] . However, in hematolymphoid malignancies, tumor-infiltrating Tregs have demonstrated different influences on the clinical outcome. High numbers of Tregs were associated with prolonged survival of patients in follicular lymphoma, Hodgkin's lymphoma, and cutaneous T-cell lymphoma [16] [17] [18] . There were conflicting results on the prognostic implications of tumor-infiltrating Tregs in diffuse large B-cell lymphomas [19, 20] . Based on these observations, it was suspected that Tregs in hematolymphoid malignancies might suppress the neoplastic lymphoid cell itself, thereby improving the clinical outcome in certain types of malignant lymphomas.
NKTCL often shows infiltration of many reactive inflammatory cells, including small lymphocytes, plasma cells, and histiocytes [1] . However, there are few reports on the tumor microenvironment or tumor-infiltrating Tregs in NKTCL. Tregs were initially identified as CD4+CD25high+ T cells; however, FOXP3 is now regarded as the most specific marker of Tregs and a key molecule for their immune suppressive function [8] . Therefore, to determine the biological meaning and the prognostic implication of Tregs in NKTCL, we quantified the FOXP3-positive Tregs in NKTCL tissues and analyzed the results, along with the clinicopathological features and patient outcomes.
patients and methods

patients and samples
Sixty-four patients were selected with pathologically proven NKTCL diagnosed from 1990 to 2007 at the Seoul National University Hospital. Histology, immunophenotype, and EBV status were reviewed to confirm the diagnosis based on the guidelines of the World Health Organization [1] . The clinical data contained the following information: primary site, involved sites, Eastern Cooperative Oncology Group performance status (PS), LDH level, systemic B symptoms, regional lymphadenopathy, bone marrow involvement, Ann Arbor stage, IPI, NKPI, treatment modality, date of diagnosis, date of last follow-up, progression, and survival status. The primary site of the tumor was classified into UAT and non-UAT. UAT was further subclassified into nasal UAT (nasal cavity or nasopharynx) and extranasal UAT (oral cavity, oropharynx, or hypopharynx). The Institutional Review Board of the Seoul National University Hospital approved this study.
Representative formalin-fixed paraffin-embedded tissues obtained from surgical resection (n = 13) or biopsy (n = 51) were submitted to further immunohistochemistry and EBV study. Tissues from relapsed tumors (from four patients) and those from separate sites simultaneously affected by tumors (in two patients) were also examined. Infiltration of FOXP3-positive Tregs was analyzed in six tissues with chronic paranasal sinusitis to evaluate their density in the non-neoplastic condition.
histopathologic examination and evaluation of EBV infection
Cytomorphology of the tumor was classified into small/medium or large/anaplastic based on the predominant cell population. Immunohistochemistry for CD3, CD20, Ki-67 (DakoCytomation, Copenhagen, Denmark), CD56 (Zymed, San Francisco, CA), and granzyme B (Lab Vision, Fremont, CA) were carried out using the labeled streptavidin-biotin peroxidase complex method. EBV infection was evaluated using the fluorescein-conjugated EBER1/2 oligonucleotide probes and an in situ hybridization detection kit (Novocastra, Newcastle, UK).
immunohistochemistry for FOXP3 and quantification of FOXP3-positive Tregs
Immunohistochemical staining for FOXP3 was done using 236A/E7 anti-FOXP3 murine monoclonal antibody (eBioscience, San Diego, CA). After heat-induced antigen retrieval by microwave, sections were incubated with 1 : 50 dilution of anti-FOXP3 antibody for overnight at 4°C. For detection, the DAKO Real Envision Detection system (DakoCytomation) was applied. Validation of FOXP3 immunostaining was done in every experiment, with reactive tonsil as a control.
The number of tumor-infiltrating FOXP3-positive Tregs was counted in a representative tumor area using an automated slide scan microscope (dotSlide, Olympus, Hamburg, Germany) with slide viewer and image analysis program (ImageJ 1.37a, downloaded from http://rsb.info.nih.gov/ ij). Briefly, a whole immunostained slide was automatically scanned at high magnification with the ·20 objective in the digital virtual microscope. Then, a representative tumor area for optimal evaluation of the FOXP3-positive cells was selected and captured from the scanned image using the virtual microscope slide viewer (Olyvia, downloaded from http:// www.olysia.co.kr/). A representative tumor area was defined as having tumor cells in >80% of the area. A tumor area was avoided if it showed marked necrosis in >20% of the area or had an ulcer and inflamed granulation tissue. A snapshot of the tumor at ·10 magnifications in the Olyvia slide viewer was equivalent to an area of 0.40 mm 2 . Then, the number of tumor-infiltrating FOXP3-positive Tregs was scored automatically through analysis of the captured image using the software (ImageJ 1.37a). At least three representative foci in each tumor were evaluated.
statistical analysis
The correlations between clinicopathological parameters and the number of tumor-infiltrating FOXP3-positive Tregs were assessed by chi-square test or Fisher's exact test after transformation into categorical values. Overall survival (OS) was measured from the date of diagnosis to the date of death or to the date of the last follow-up visit. Progression-free survival (PFS) was calculated from the date of diagnosis to the date of disease progression, death, or the date of the last follow-up visit. Survival analysis was carried out using the Kaplan and Meier method using the log-rank test. Univariate and multivariate analyses were done using the Cox proportional hazard model. Two-sided P values <0.05 were considered to be statistically significant. Statistical analysis was carried out using SPSS versions 12.0 (SPSS Inc., Chicago, IL).
results
patient characteristics
The main clinicopathological characteristics of the 64 patients are summarized in Table 1 . The median age of patients was
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50 years (range 10-79 years). The majority of patients initially presented with tumors of the UAT (83%) or stage I/II (75%) disease and was categorized into the low-risk IPI or NKPI (IPI 0-1, 70%; NKPI 1-2, 67%). Primary non-UAT cases involved small bowel, colon, skin, soft tissue, and lung. Patients were additionally classified into five treatment groups based on the initial treatment modality and the chemotherapy regimen as shown in Table 1 . These five groups encompassed cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like chemotherapy only (n = 9), ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) chemotherapy only (n = 20), CHOP-like chemotherapy followed by radiotherapy (n = 7), IMEP chemotherapy followed by radiotherapy (n = 16), and others (n = 11). EBV infection was detected in all the 64 cases. (Figure 2 ), most cases belonged to one of the two end groups, which were the low-end group, with Tregs <50/0.40 mm 2 , and the high-end group, with Tregs >200/0.40 mm 2 . To determine the optimal cutoff value of Treg numbers having prognostic discriminating power, the receiver operator characteristic (ROC) curves were plotted. The optimal cutoff value was closely approximated to 50/0.40 mm 2 with the sensitivity of 70.4% and specificity of 73.5%. The correlations between the number of FOXP3-positive Tregs and main clinicopathological parameters are summarized in Table 2 . Decreased numbers of tumor-infiltrating Tregs (<50/ 0.40 mm 2 ) were significantly associated with a poor PS or a primary non-UAT site of tumor (P = 0.014 and 0.007, respectively). Of 11 NKTCL patients with a primary non-UAT site, nine (82%) had low numbers of Tregs (<50/0.40 mm 2 ). However, there were no significant relationships between the numbers of tumor-infiltrating Tregs and other prognostic Annals of Oncology original article factors including stage, LDH level, number of extranodal sites, B symptoms, regional lymphadenopathy, bone marrow involvement, IPI score, NKPI group, and tumor cell size. These data implied that risk factors were well balanced between NKTCL cases with increased numbers of Tregs and those with decreased Tregs in our study cohort.
the number of tumor-infiltrating FOXP3-positive Tregs and survival of patients
The 5-year OS rate of the 64 NKTCL patients in this study was 48.3% with a median OS of 60.5 months. The PFS rate was 29.1% at 5 years. The clinical factors which adversely affected patient survival in the univariate analysis were as follows: advanced stage (stage III/IV), elevated LDH, presence of systemic symptoms, involvement of two or more extranodal sites, PS of two or higher, and primary non-UAT site of tumor ( Table 3 ). The IPI score had strong prognostic implications when divided into two categories (low versus intermediate-to-high risk) (P < 0.0001). Similarly, the NKPI score was associated with prognosis when subdivided into two categories, namely low risk (groups 1 and 2) versus high risk (groups 3 and 4) (P < 0.0001). Regional lymphadenopathy and bone marrow involvement had no significant prognostic meaning.
NKTCL patients with a high number of tumor-infiltrating FOXP3-positive Tregs exhibited significantly longer OS and PFS (5-year OS, 71% in those with Tregs ‡ 50/0.40 mm 2 versus 25% in those with Tregs < 50/0.40 mm 2 , P = 0.0005; 3-year PFS, 41% in those with Tregs ‡ 50/0.40 mm 2 versus 21% in those with Tregs < 50/0.40 mm 2 , P = 0.0079) ( Figure 3A and B) . Furthermore, in subgroup analysis, the increased number of Tregs was significantly associated with improved survival irrespective of IPI, NKPI, and stage ( Figure 4A-F) . When analyzed according to the primary site, the favorable prognostic implication of increased Tregs was also observed in UAT-NKTCL (P = 0.0091) or in nasal UAT-NKTCL (P = 0.0018) ( Figure 4G and H) . However, survival analysis among the non- 
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UAT-NKTCL could not be carried out because of the limited number of cases. The prognostic value of Tregs was also maintained when considering the treatment modality. Namely, the increased Tregs was significantly associated with prolonged OS when analyzed among patients treated with chemotherapy alone (P = 0.0109), IMEP chemotherapy alone (P = 0.0001), and IMEP-based chemo-or chemoradiotherapy (P < 0.0001), respectively.
survival predictor
Finally, to determine the importance of tumor-infiltrating FOXP3-positive Treg numbers as an independent prognostic factor, multivariate survival analysis was carried out using the Cox proportional hazard model, including all factors revealed to be related to prognosis by the univariate analysis (Table 3 ). In the analysis of all cases, the decreased number of Tregs and high LDH levels were the only independent poor prognostic indicators (P = 0.001 and P = 0.003, respectively). When analyzed among the patients with IPI 0-1 or those with NKPI 1-2, the decreased number of Tregs was the only significant predictor for shorter survival [hazard ratio (HR) 7.079, P = 0.019; or HR 5.936, P = 0.021, respectively]. In an analysis integrating the IPI or NKPI group, the number of Tregs was also an independent prognostic factor (P = 0.002).
Moreover, the multivariate analysis of nasal UAT-NKTCL cases revealed that the number of Tregs had a strong independent prognostic implication for NKTCLs presenting at the nasal site (Table 4) . To exclude the effect of treatment on the prognosis of patients, multivariate survival analyses were carried out in subpopulations treated with IMEP chemotherapy only or with IMEP-based chemo-or chemoradiotherapy. In the result, the number of Tregs was a strong independent prognostic indicator in each analysis (data not shown).
discussion Here, we demonstrated that the high number of tumorinfiltrating FOXP3-positive Tregs predicts prolonged survival of NKTCL patients. In addition, although the number of tumorinfiltrating Tregs in NKTCL could be separated into two end groups, the quantity of Tregs was not correlated with any other clinical prognostic parameters, except for the PS and the primary tumor site. In the present study, tumor-infiltrating FOXP3-positive Tregs were much rarer in non-UAT-NKTCLs than in UAT-NKTCLs and in patients with poor PS, which might lead to poor clinical outcome of patients with decreased Tregs. However, in multivariate analysis, a paucity of Tregs was independently associated with poor clinical outcome of NKTCL patients regardless of the primary site involved and PS. Furthermore, the quantity of Tregs had an independent prognostic value in analyses confined to UAT-or nasal NKTCLs. Therefore, it is possible that Tregs might infiltrate the NKTCL in a different manner depending to site involvement, but still have prognostic value irrespective of primary tumor site. Moreover, the independent prognostic implication of the quantity of Tregs was consistently observed in analyses of NKTCL patients treated with homogeneous modality. These observations suggest that infiltration of FOXP3-positive Tregs in the tumor microenvironment might reflect a unique and clinically important biological aspect of NKTCL. Despite its distinct pathological and genetic characteristics, NKTCL exhibits variable clinical features and behaviors. As mentioned, many clinical and pathological efforts have been made to identify prognostic markers in NKTCL. Pathologically, loss of the granzyme B protease inhibitor 9, Cox-2 expression, and high Ki-67 expression has been associated with poor prognosis of NKTCL [21] [22] [23] . Based on our results, the evaluation of tumor-infiltrating FOXP3-positive Tregs would provide useful information for the risk stratification of NKTCL. Increases of Tregs in peripheral blood and tumor tissues have been reported in both carcinomas and hematolymphoid malignancies; however, the influences of Tregs on the tumor cells and patient outcome have been conflicting [13-20, 24, 25] . This study further suggests that tumor-infiltrating Tregs might suppress not only cytotoxic T cells related to antitumor immune responses but also, probably more efficiently, neoplastic lymphoid cells, which share the properties of normal counterpart cells and would be susceptible to Treg-mediated inhibition, and thereby contribute to the improved clinical outcome in lymphomas. However, the strengths of the prognostic effect of Tregs were different among the types of lymphoma reported [16] [17] [18] [19] [20] . As we know, the favorable influence of tumor-infiltrating Tregs on clinical outcome was most significant in NKTCL, as observed in this study. It is also noteworthy that the extent to which tumor-infiltrating Tregs correlated with clinical outcome might vary among lymphoma types. These findings imply that the influence of the tumor microenvironment or Tregs on the behaviors of lymphomas might depend on the tumor type.
Considering the mechanisms underlying Treg-mediated suppression of immune cells including NK cells [9] [10] [11] , several possibilities might explain the antitumor effect of FOXP3-positve Tregs in NKTCL. To begin with, Tregs constitutively overexpress CD25, the high-affinity receptor for interleukin-2 (IL-2), with which they bind IL-2. It was shown that Tregs could inhibit NK cells in an IL-2-dependent manner, not only by the suppression of IL-2 production of T helper cells but also by the consumption of IL-2 [26] . IL-2 is an important cytokine essential for the proliferation and maintenance of NKTCL cell lines in culture [27] . Taken together, it is possible that tumor-infiltrating Tregs might compete for IL-2 with tumor cells of NKTCL, causing the local deprivation of IL-2 and thereby exerting an antitumor effect while improving the clinical outcome. Inhibition of NK cells by Tregs is also mediated by the interaction between the TGF-b of Tregs and the TGF-b receptor of the NK cell, which resulted in suppression of NK cell proliferation and blocked expression of the molecules related to cytotoxic function or cytokine production, such as IFN-c in NK cells [9] [10] [11] . Therefore, it is possible that increased tumor-infiltrating Tregs might suppress tumor cells in a TGF-b-mediated way and create an inhibitory tumor microenvironment in NKTCL. Tregs also suppress cytotoxic T cell (another cells from which NKTCL rarely originates) through variable mechanisms, including cytokine (TGF-b and IL-10)-dependent or -independent inhibition, IL-2 deprivation, and direct cytotoxicity through the release of granzyme B and perforin [8, 10] . To assess the tumorinfiltrating Tregs on the proliferation of tumor cells in NKTCL, we evaluated the Ki-67 proliferation index of tumor by immunohistochemistry and compared it with the quantity of Tregs. The mean value of Ki-67 proliferation index was lower in NKTCLs with increased Tregs ( ‡50/0.40 mm Several cytokines, including IFN-c, IL-10, and TNF-a, were frequently detected in NKTCL, which suggests that tumor cells in NKTCL maintain the immunologic activity to produce cytokines [28, 29] . This cytokine production by tumor cells might be related to the progression of NKTCL, the inflammatory cell infiltrations, and probably the recruitment of Tregs within a tumor. NKTCL is consistently infected by EBV in nearly all tumor cells, and the latency of EBV in NKTCL is type 2 expressing Epstein-Barr virus nuclear antigen 1 (EBNA1), latent membrane protein (LMP) 1 and LMP2, along with Hodgkin's lymphoma and nasopharyngeal carcinoma. In terms of EBV-associated malignancies and Tregs, a few reports are available. Antigen presentation by nasopharyngeal carcinoma-associated LMP1 transfectants to CD4+ T helper cells potentiated Treg function, but not normal B cellassociated LMP1 [30] . Expression of EBNA1 in Hodgkin's lymphoma cells resulted in the upregulation of CCL20, a ligand for CCR6 expressed in Tregs, and thereby mediated the migration of Tregs [31] . CCL20 was also consistently expressed in the EBV-infected nasopharyngeal carcinomas [31] . Although we did not evaluate the expression of LMP1, EBNA1 and CCL20 in NKTCL, the aforementioned studies suggest that EBV might be involved in the infiltration of FOXP3-postive Tregs in some NKTCLs.
In conclusion, this study demonstrates that a high quantity of tumor-infiltrating FOXP3-positive Tregs is strongly and independently correlated with prolonged survival in NKTCL, when compared with previously known prognostic factors including stage, IPI, NKPI, and primary tumor site. These results also suggest that the role of Tregs in terms of immunological tumor microenvironment would be important for the biological behavior of NKTCL and that the quantity of tumor-infiltrating Tregs could be used as a novel prognostic marker for the appropriate management of patients. 
